Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2016 call → NOWe need answer only YES or NO. Need analyze transcript. Need determine if management describes company as currently living through defined waiting period paying out of pocket, with cost now, wait is main work, far side specific near-dated event already visible and working toward. Let's parse. Company ANI. They discuss Corticotropin project. They have hired people, manufacturing, analytics, regulatory. They are investing R&D increasing primarily due to Corticotropin. They have not met FDA, need to meet before sNDA. They don't disclose timelines. They are developing. Is this a waiting period? They are paying now for something not yet earning: Corticotropin asset acquired, R&D spend, employees dedicated. But is there a specific near-dated event? They do not publicly disclose internal timelines. They say "We hope to launch NDA as authorized generic" for HPC, but that's different. For Corticotropin, no timeline. They say "We have begun work on manufacturing raw material batches, analytical method development and have recently hired Karen Quinn to lead regulatory filing strategy." They need FDA meeting before sNDA. The far side is not specific near-dated; they explicitly don't disclose internal timelines. Also need approvals (FDA) not yet granted. So NO. But maybe other aspects? They terminated HPC distribution agreement, received cash and NDA, hope to launch authorized generic in near future. That is a waiting? They received cash and NDA, no cost? Not paying. They have product launches in 2017, but those are normal growth. They have Inderal LA etc. They have R&D investment. But the question asks "does management describe company as CURRENTLY LIVING THROUGH A DEFINED WAITING PERIOD IT IS PAYING FOR OUT OF ITS OWN POCKET" with end specific near-dated. Corticotropin is main but no timeline. Also they say "We are not publicly disclosing internal timelines." So no. Need answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.